Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes - Full Text View

Sponsor:	Massachusetts General Hospital
Information provided by:	Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00946192

Purpose

The purpose of this study is to determine if transdermal estrogen or oral estrogen are effective in the treatment of amenorrhea in adolescent athletes. Special attention will be paid to how these treatments affect bone health in these patients. The investigators hypothesize that transdermal estrogen will be more effective than oral estrogen or no estrogen in improving bone health in amenorrheic adolescent athletes.

Condition	Intervention	Phase
Amenorrhea Female Athlete Triad Syndrome	Drug: Transdermal 17Beta-estradiol, progesterone Drug: Ethinyl Estradiol + Desogestrel Dietary Supplement: Elemental Calcium and Vitamin D	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study
Official Title:	Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes

Resource links provided by NLM:

MedlinePlus related topics: Calcium

Drug Information available for: Estradiol Estradiol 3-benzoate Ethinyl estradiol Progesterone Polyestradiol phosphate Desogestrel Depogen Estradiol dipropionate Calcium gluconate Estradiol cypionate Estradiol valerate Vitamin D Estradiol acetate

U.S. FDA Resources

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:

We will test the hypothesis that in adolescent amenorrheic athletes,transdermal estradiol administration leads to an increase in bone accrual rates [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment:	230
Study Start Date:	May 2009
Estimated Study Completion Date:	November 2014
Estimated Primary Completion Date:	May 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Estrogen Patch: Experimental 17Beta-estradiol transdermal patch twice weekly application for 12 months	Drug: Transdermal 17Beta-estradiol, progesterone 100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
Estrogen Pill: Active Comparator One pill containing estrogen and progesterone taken daily for 21 days followed by one pill containing progesterone only for 7 days; regimen repeated for 12 months.	Drug: Ethinyl Estradiol + Desogestrel Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
No Estrogen: No Intervention	Dietary Supplement: Elemental Calcium and Vitamin D Elemental calcium 1200 mg and Vitamin D 400 IU taken once daily

Detailed Description:

As many as 25% of adolescent and young adult endurance athletes develop amenorrhea, and factors that cause amenorrhea to occur in some, but not all, athletes have not been well characterized. Recent data indicate the critical importance of a negative energy balance state and leptin in regulating the Hypothalamic-pituitary-gonadal (H-P-G) axis. However, these factors do not completely account for alterations in this axis, and other contributing factors are unclear. Our preliminary data indicate the importance of low fat mass and fat related hormones in mediating hypogonadism in young athletes. This study will confirm these data and determine whether low fat mass and altered levels of adipokines, such as leptin and adiponectin, and hormones regulated by fat mass, such as ghrelin and peptide YY (PYY), determine alterations in LH pulsatility. A very concerning impact of amenorrhea in athletes is low bone mineral density (BMD). Preliminary data indicate lower BMD in adolescent athletes with amenorrhea (AA) compared with eumenorrheic athletes (EA) and non-athletic controls. The high prevalence of AA in adolescents is particularly concerning, because this population is potentially at greater risk as it is actively accruing bone. Of importance, bone microarchitecture, a better predictor of bone strength than BMD, has not been studied in AA. Because pubertal increases in estrogen are integral to optimizing peak bone mass, and AA is characterized by hypoestrogenism, this randomized study of transdermal estrogen versus oral estrogen or no estrogen will also examine whether estrogen replacement increases BMD and improves bone microarchitecture in adolescent AA 14-21 years old. EA and sedentary controls will be followed without intervention for this period. Despite the prevalent practice of prescribing oral contraceptives in AA, there is a paucity of data regarding benefits of this intervention in teenagers. Because transdermal estrogen, unlike oral estrogen, does not suppress IGF-1, an important bone anabolic factor, we expect effects of transdermal estrogen to exceed those of oral estrogen or no therapy. In addition, preliminary data indicate that low fat mass and alterations in fat related hormones may contribute to decreased bone accrual rates in athletes, and will be confirmed in this study. To summarize, a better understanding of the pathophysiology of reproductive dysfunction is critical to develop therapeutic strategies that will normalize the reproductive axis and bone accrual, and these are the questions that this study aims to answer.

Eligibility

Ages Eligible for Study:	14 Years to 21 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Females 14-21 years old Note: Our pilot data are reassuring in that young women 18-25 years old with hypothalamic amenorrhea are not adversely affected with estrogen use. In fact, in our prospective study, beneficial effects were observed both in young women 18-25 years old using oral estrogen, and in 14-18 year old adolescent girls using transdermal estrogen. We therefore feel that including girls in the 14-21 year age range will not be hazardous to their bone health. In fact, given the lack of data in this age group, it is important to study younger women and teenagers rather than extrapolate data from studies in adults to this younger population. Hormone dynamics differ in teenagers compared with adults, and bone mass accrual is even more dependent on estrogen and IGF-1 in younger than older women who have already achieved peak bone mass.
Bone age (BA) >15 years Note: 99% of adult height is achieved at a BA of 15 years, thus estrogen replacement will not result in stunting of height potential after this age. Although we could have chosen to include girls with a BA >14 in this study, we are limiting this to girls with a BA of >15 years. This is because 2% of growth potential persists at a BA of 14 years, versus only 1% at a BA of 15 years (~0.6" of potential height (130)). Thus, to avoid potential stunting of growth potential with estrogen replacement, we have chosen to include girls with BA of > 15 years.
BMI between 10th-90th percentiles for age.
Amenorrhea (for AA): absence of menses for > three months (74) within a period of oligomenorrhea (cycle length > six weeks) for >six months, or absence of menarche at >16 years.
Eumenorrhea (EA and controls): > nine menses (cycle length 21-35 days) in preceding year.
Non-athlete healthy controls will be eligible if weight bearing exercise activity is less than two hours a week and if they are not participating in organized team sports.
Endurance athletes Note: severity of low BMD and menstrual dysfunction differ by kind of exercise and activity. For example, runners have a higher prevalence of menstrual irregularity than swimmers and cyclists (131). By limiting enrollment to endurance athletes, we will eliminate variability from the type of activity. Endurance training is defined as > 4 h of aerobic weight-bearing training of the legs or specific endurance training weekly, or > 20 miles of running weekly for a period of > 6 months in the last year.

Exclusion Criteria:

None.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00946192

Contacts

Contact: Madhusmita Misra, MD, MPH

617-724-5602

mmisra@partners.org

Locations

United States, Massachusetts
Massachusetts General Hospital	Recruiting
Boston, Massachusetts, United States, 02114
Contact: Madhu Misra, M.D. 617-724-5602 mmisra@partners.org
Contact: Nara Mendes, B.A. 617 724 6046 nmendes1@partners.org
Principal Investigator: Madhu Misra, M.D.

Sponsors and Collaborators

Massachusetts General Hospital

Investigators

Principal Investigator:

Madhusmita Misra, MD, MPH

Massachusetts General Hospital Pediatric Neuroendocrine Unit and Harvard Medical School

More Information

Additional Information:

Click here for up-to-date information about the Neuroendocrine Unit at Massachusetts General Hospital including ongoing research studies, staff listing, and educational resources. This link exits the ClinicalTrials.gov site

This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	MassGeneral Hospital for Children and Harvard Medical School ( Madhusmita Misra, MD, MPH/ Program Director, Pediatric Endocrinology )
Study ID Numbers:	2009P000353, R01 HD060827-01A1
Study First Received:	July 22, 2009
Last Updated:	August 7, 2009
ClinicalTrials.gov Identifier:	NCT00946192 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Massachusetts General Hospital:

Amenorrhea
Adolescent
Endurance
Athletes

Females
Osteopenia
Osteoporosis
Estrogen

Additional relevant MeSH terms:

Progesterone
Contraceptive Agents
Gonadal Disorders
Contraceptives, Oral
Physiological Effects of Drugs
Estradiol valerate
Contraceptive Agents, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Amenorrhea
Bone Density Conservation Agents
Reproductive Control Agents
Estradiol 17 beta-cypionate
Hormones
Bone Diseases
Prune Belly Syndrome

Pathologic Processes
Desogestrel
Musculoskeletal Diseases
Menstruation Disturbances
Mental Disorders
Progestins
Therapeutic Uses
Estradiol 3-benzoate
Syndrome
Vitamins
Abnormalities, Multiple
Female Athlete Triad Syndrome
Contraceptives, Oral, Synthetic
Micronutrients
Congenital Abnormalities

ClinicalTrials.gov processed this record on February 08, 2010